This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cerebrovascular Disease  • Stroke  • Radiologic Imaging  • PET/ SPECT Imaging  • Alert me on articles by topic  Social Bookmarking   What's this?

William C. Kreisl, MD; Gilbert Mbeo, MD; Masahiro Fujita, MD, PhD; Sami S. Zoghbi, PhD; Victor W. Pike, PhD; Robert B. Innis, MD, PhD; Justin C. McArthur, MBBS, MPH

Arch Neurol. 2009;66(10):1288-1289.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A 42-year-old man enrolled in a research study to measure microglial activation using [O-methyl-¹¹C] N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine ([¹¹C]PBR28), an improved positron emission tomography (PET) radioligand. His history included human immunodeficiency virus infection, diabetes, hypertension, hypercholesterolemia, smoking (12 pack-years), and remote use of cocaine and heroin. Medical and neurological examination results were normal except for elevated blood pressure of 157/100 mm Hg. Brain magnetic resonance imaging (MRI) showed occasional foci of mild chronic white matter ischemia but was otherwise unremarkable (Figure, A).

Figure appears in full text version. Figure. Imaging results. A, The original T1-weighted magnetic resonance image has mild white matter ischemic changes (not seen at the level shown) but is otherwise unremarkable. B, The [O-methyl-11C]N. . . [Full Text of this Article]

COMMENT


AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?